Knight Therapeutics Inc. reconfirmed earnings guidance for the year 2024. Knight expects to generate between $335 million to $350 million in revenues.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.45 CAD | +0.37% | -7.00% | +5.01% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.01% | 401M | |
+13.67% | 78.98B | |
+13.06% | 8.89B | |
-22.91% | 4.36B | |
+33.84% | 4.29B | |
+10.76% | 4.1B | |
+6.75% | 2.16B | |
-30.28% | 2.13B | |
+8.58% | 2.01B | |
-44.99% | 1.75B |
- Stock Market
- Equities
- GUD Stock
- News Knight Therapeutics Inc.
- Knight Therapeutics Inc. Reconfirms Earnings Guidance for the Year 2024